Synergistic interaction of endogenous platelet-activating factor and vasopressin in generating angina in rats

János Nemcsik, Krisztina Kordás, József Egresits, F. László, F. László, Imre Pávó, E. Morschl

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We examined the involvement of endogenous vasopressin and platelet-activating factor (PAF) in the pathogenesis of two types of experimental angina in urethane-anaesthetised male Wistar rats. In the first model, epinephrine (10 μg kg -1) was injected into the tail vein, followed at the development of the maximum blood pressure response, i.e., 30 s later, by phentolamine (15 mg kg -1). In the second model, the vasopressin V 1 receptor agonist ornithine-vasopressin (ornipressin; 0.5 IU kg -1, i.v.) was administered. The heart rate, mean arterial blood pressure and surface electrocardiogram (ECG, standard lead II) were registered simultaneously. As a measure of myocardial ischaemia, at 1 min after phentolamine or ornipressin administration, we found significant ST-segment depression, lasting for more than 10 or 5 min, respectively. Pretreatment (15 min, s.c.) with the vasopressin V 1 receptor antagonist Mca 1,Tyr(Me) 2AVP (the Manning peptide; 0.02-0.2 μg kg -1) or the platelet-activating factor receptor antagonist ginkgolide B (BN 52021; 0.25-2.5 mg kg -1) alone caused a dose-dependent reduction of the ST-segment depression. Concurrent administration of the two antagonists in their threshold doses (0.02 μg kg -1 and 0.25 mg kg -1) also attenuated the ST-segment depression in both models. Neither antagonist affected the blood pressure or heart rate changes throughout the studies. Our results suggest that endogenous vasopressin and platelet-activating factor interact synergistically in provoking myocardial ischaemia in vivo in experimental angina in the rat.

Original languageEnglish
Pages (from-to)195-202
Number of pages8
JournalEuropean Journal of Pharmacology
Volume498
Issue number1-3
DOIs
Publication statusPublished - Sep 13 2004

Fingerprint

Ornipressin
ginkgolide B
Platelet Activating Factor
Vasopressins
Vasopressin Receptors
Phentolamine
Myocardial Ischemia
Arterial Pressure
Electrocardiography
Heart Rate
Blood Pressure
Urethane
Epinephrine
Tail
Wistar Rats
Veins
Peptides

Keywords

  • Experimental angina
  • Pathogenesis of myocardial ischaemia
  • Platelet-activating factor
  • Synergistic interaction
  • Vasopressin

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Synergistic interaction of endogenous platelet-activating factor and vasopressin in generating angina in rats. / Nemcsik, János; Kordás, Krisztina; Egresits, József; László, F.; László, F.; Pávó, Imre; Morschl, E.

In: European Journal of Pharmacology, Vol. 498, No. 1-3, 13.09.2004, p. 195-202.

Research output: Contribution to journalArticle

@article{5b0c075dae2c4f739da7addf0b91f613,
title = "Synergistic interaction of endogenous platelet-activating factor and vasopressin in generating angina in rats",
abstract = "We examined the involvement of endogenous vasopressin and platelet-activating factor (PAF) in the pathogenesis of two types of experimental angina in urethane-anaesthetised male Wistar rats. In the first model, epinephrine (10 μg kg -1) was injected into the tail vein, followed at the development of the maximum blood pressure response, i.e., 30 s later, by phentolamine (15 mg kg -1). In the second model, the vasopressin V 1 receptor agonist ornithine-vasopressin (ornipressin; 0.5 IU kg -1, i.v.) was administered. The heart rate, mean arterial blood pressure and surface electrocardiogram (ECG, standard lead II) were registered simultaneously. As a measure of myocardial ischaemia, at 1 min after phentolamine or ornipressin administration, we found significant ST-segment depression, lasting for more than 10 or 5 min, respectively. Pretreatment (15 min, s.c.) with the vasopressin V 1 receptor antagonist Mca 1,Tyr(Me) 2AVP (the Manning peptide; 0.02-0.2 μg kg -1) or the platelet-activating factor receptor antagonist ginkgolide B (BN 52021; 0.25-2.5 mg kg -1) alone caused a dose-dependent reduction of the ST-segment depression. Concurrent administration of the two antagonists in their threshold doses (0.02 μg kg -1 and 0.25 mg kg -1) also attenuated the ST-segment depression in both models. Neither antagonist affected the blood pressure or heart rate changes throughout the studies. Our results suggest that endogenous vasopressin and platelet-activating factor interact synergistically in provoking myocardial ischaemia in vivo in experimental angina in the rat.",
keywords = "Experimental angina, Pathogenesis of myocardial ischaemia, Platelet-activating factor, Synergistic interaction, Vasopressin",
author = "J{\'a}nos Nemcsik and Krisztina Kord{\'a}s and J{\'o}zsef Egresits and F. L{\'a}szl{\'o} and F. L{\'a}szl{\'o} and Imre P{\'a}v{\'o} and E. Morschl",
year = "2004",
month = "9",
day = "13",
doi = "10.1016/j.ejphar.2004.07.057",
language = "English",
volume = "498",
pages = "195--202",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Synergistic interaction of endogenous platelet-activating factor and vasopressin in generating angina in rats

AU - Nemcsik, János

AU - Kordás, Krisztina

AU - Egresits, József

AU - László, F.

AU - László, F.

AU - Pávó, Imre

AU - Morschl, E.

PY - 2004/9/13

Y1 - 2004/9/13

N2 - We examined the involvement of endogenous vasopressin and platelet-activating factor (PAF) in the pathogenesis of two types of experimental angina in urethane-anaesthetised male Wistar rats. In the first model, epinephrine (10 μg kg -1) was injected into the tail vein, followed at the development of the maximum blood pressure response, i.e., 30 s later, by phentolamine (15 mg kg -1). In the second model, the vasopressin V 1 receptor agonist ornithine-vasopressin (ornipressin; 0.5 IU kg -1, i.v.) was administered. The heart rate, mean arterial blood pressure and surface electrocardiogram (ECG, standard lead II) were registered simultaneously. As a measure of myocardial ischaemia, at 1 min after phentolamine or ornipressin administration, we found significant ST-segment depression, lasting for more than 10 or 5 min, respectively. Pretreatment (15 min, s.c.) with the vasopressin V 1 receptor antagonist Mca 1,Tyr(Me) 2AVP (the Manning peptide; 0.02-0.2 μg kg -1) or the platelet-activating factor receptor antagonist ginkgolide B (BN 52021; 0.25-2.5 mg kg -1) alone caused a dose-dependent reduction of the ST-segment depression. Concurrent administration of the two antagonists in their threshold doses (0.02 μg kg -1 and 0.25 mg kg -1) also attenuated the ST-segment depression in both models. Neither antagonist affected the blood pressure or heart rate changes throughout the studies. Our results suggest that endogenous vasopressin and platelet-activating factor interact synergistically in provoking myocardial ischaemia in vivo in experimental angina in the rat.

AB - We examined the involvement of endogenous vasopressin and platelet-activating factor (PAF) in the pathogenesis of two types of experimental angina in urethane-anaesthetised male Wistar rats. In the first model, epinephrine (10 μg kg -1) was injected into the tail vein, followed at the development of the maximum blood pressure response, i.e., 30 s later, by phentolamine (15 mg kg -1). In the second model, the vasopressin V 1 receptor agonist ornithine-vasopressin (ornipressin; 0.5 IU kg -1, i.v.) was administered. The heart rate, mean arterial blood pressure and surface electrocardiogram (ECG, standard lead II) were registered simultaneously. As a measure of myocardial ischaemia, at 1 min after phentolamine or ornipressin administration, we found significant ST-segment depression, lasting for more than 10 or 5 min, respectively. Pretreatment (15 min, s.c.) with the vasopressin V 1 receptor antagonist Mca 1,Tyr(Me) 2AVP (the Manning peptide; 0.02-0.2 μg kg -1) or the platelet-activating factor receptor antagonist ginkgolide B (BN 52021; 0.25-2.5 mg kg -1) alone caused a dose-dependent reduction of the ST-segment depression. Concurrent administration of the two antagonists in their threshold doses (0.02 μg kg -1 and 0.25 mg kg -1) also attenuated the ST-segment depression in both models. Neither antagonist affected the blood pressure or heart rate changes throughout the studies. Our results suggest that endogenous vasopressin and platelet-activating factor interact synergistically in provoking myocardial ischaemia in vivo in experimental angina in the rat.

KW - Experimental angina

KW - Pathogenesis of myocardial ischaemia

KW - Platelet-activating factor

KW - Synergistic interaction

KW - Vasopressin

UR - http://www.scopus.com/inward/record.url?scp=4444225873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444225873&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2004.07.057

DO - 10.1016/j.ejphar.2004.07.057

M3 - Article

C2 - 15363995

AN - SCOPUS:4444225873

VL - 498

SP - 195

EP - 202

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -